D. J. Kwekkeboom

Medicine · Health Sciences

24h-index1.9kcitations42works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroendocrine Tumor Research Advances(27), Neuroblastoma Research and Treatments(19), Lung Cancer Research Studies(14), Radiopharmaceutical Chemistry and Applications(10), Thyroid Cancer Diagnosis and Treatment(3)

Publications42 total

NETTER-1 Phase III Trial : Recent Findings on Quality of Life in Patients with Midgut Neuroendocrine Tumors
Neuroendocrinology·2017· 2 cited
NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate: Efficacy, Safety, QoL Results and Subgroup Analysis
Endocrine Abstracts·2016· 5 cited
NETTER-1 phase III in patients with midgut neuroendocrine tumors treated with 177Lu-dotatate: Efficacy, safety, QoL results and subgroup analysis
Annals of Oncology·2016· 3 cited
O-009 NETTER-1 phase III: efficacy and safety results in patients with midgut neuroendocrine tumors treated with 177Lu-dotatate
Annals of Oncology·2016· 5 cited
SP-0570: Neuroendocrine tumours - personalised diagnosis and treatment using radiolabelled peptides
Radiotherapy and Oncology·2016Open Access
Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors
European Journal of Nuclear Medicine and Molecular Imaging·2015· 141 cited
6LBA 177-Lu-Dotatate significantly improves progression-free survival in patients with midgut neuroendocrine tumours: Results of the phase III NETTER-1 trial
European Journal of Cancer·2015· 56 cited
Gene transcript analysis blood values correlate with 68Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status
European Journal of Nuclear Medicine and Molecular Imaging·2015· 46 cited
Recommendations for management of patients with neuroendocrine liver metastases. Working Group on Neuroendocrine Liver Metastases.
2015· 20 cited
Netter-1: First Pivotal Phase III Study Evaluating 177Lu-Dotatate in Midgut Neuroendocrine Tumours
Annals of Oncology·2014· 1 citedOpen Access
Erratum to: The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
European Journal of Nuclear Medicine and Molecular Imaging·2013· 30 citedOpen Access
The peripheral blood compartment in patients with Graves' disease: activated T lymphocytes and increased transitional and pre-naive mature B lymphocytes
Clinical & Experimental Immunology·2013· 25 citedOpen Access
Immunohistochemical localization and quantitative expression of somatostatin receptors in normal human spleen and thymus: Implications for the in vivo visualization during somatostatin receptor scintigraphy.
EUR Research Repository (Erasmus University Rotterdam)·2012· 23 cited
Peptide receptor targeted radiotherapy
13th European Congress of Endocrinology·2011
Radiolabelled Regulatory Peptides for Imaging and Therapy
Anti-Cancer Agents in Medicinal Chemistry·2007· 39 citedOpen Access
Practical aspects of peptide receptor radionuclide therapy with [177Lu][DOTA0, Tyr3]octreotate.
PubMed·2006· 45 cited
Molecular radiotherapy with somatostatin analogs for (neuro-)endocrine tumors.
PubMed·2005· 23 cited
[Cyanosis and liver cirrhosis: hepatopulmonary syndrome].
PubMed·2000
Peptide receptor imaging and therapy.
PubMed·2000· 330 cited
Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues.
PubMed·1999· 72 cited
page 1 of 3Next →

Frequent Co-authors

E. P. Krenning(18), E. P. Krenning(10), Steven W. J. Lamberts(8), Willem H. Bakker(6), Wout A. P. Breeman(6), Edward M. Wolin(6), Beth Chasen(5), David Bushnell(5), Timothy J. Hobday(5), Kjell Öberg(5), Maribel Lopera Sierra(5), J.C. Reubi(4), Lisa Bodei(4), Richard P. Baum(4), H.Y. Oei(4), Roelf Valkema(4), Andrew Hendifar(4), Pamela L. Kunz(4), Marion de Jong(3), Mark Kidd(3)